Calithera Biosciences Stock Earnings Report
Current P/E ratio: -0.0122 | Price (Feb 03, 2023, EOD): $0.175 (Find current average P/E ratios for all sectors below)
CALA Upcoming Earnings (Q4 2022)
Earnings Date: | Mar 29, 2023 |
Consensus EPS: | Premium |
CALA Analysts Price Targets
Currently no data available.About Calithera Biosciences
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Last 3 Quarters for CALA Premium
Below you can see how CALA performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Average Sector P/E ratio
Is your stock priced above or below the average P/E ratio?
A higher P/E ratio shows that investors are willing to pay a higher share price today because of growth expectations in the future. For example, a company with a current P/E of 25, trades at 25 times today's earnings.
Name | Number of firms | Average PE |
---|---|---|
Advertising | 47 | 20 |
Aerospace/Defense | 77 | 35 |
Air Transport | 18 | 15 |
Apparel | 51 | 26 |
Auto & Truck | 13 | 15 |
Auto Parts | 46 | 16 |
Bank (Money Center) | 7 | 11 |
Banks (Regional) | 611 | 17 |
Beverage (Alcoholic) | 21 | 38 |
Beverage (Soft) | 34 | 35 |
Broadcasting | 27 | 14 |
Brokerage & Investment Banking | 39 | 14 |
Building Materials | 42 | 23 |
Business & Consumer Services | 165 | 32 |
Cable TV | 14 | 156 |
Chemical (Basic) | 43 | 14 |
Chemical (Diversified) | 6 | 10 |
Chemical (Specialty) | 94 | 25 |
Coal & Related Energy | 22 | 7 |
Computer Services | 106 | 27 |
Computers/Peripherals | 48 | 24 |
Construction Supplies | 44 | 22 |
Diversified | 23 | 45 |
Drugs (Biotechnology) | 503 | 77 |
Drugs (Pharmaceutical) | 267 | 22 |
Education | 35 | 21 |
Electrical Equipment | 113 | 28 |
Electronics (Consumer & Office) | 20 | 18 |
Electronics (General) | 153 | 49 |
Engineering/Construction | 54 | 24 |
Entertainment | 107 | 150 |
Environmental & Waste Services | 82 | 70 |
Farming/Agriculture | 31 | 63 |
Financial Svcs. (Non-bank & Insurance) | 232 | 36 |
Food Processing | 88 | 55 |
Food Wholesalers | 17 | 43 |
Furn/Home Furnishings | 35 | 17 |
Green & Renewable Energy | 22 | 88 |
Healthcare Products | 242 | 160 |
Healthcare Support Services | 128 | 131 |
Heathcare Information and Technology | 129 | 132 |
Homebuilding | 32 | 64 |
Hospitals/Healthcare Facilities | 36 | 145 |
Hotel/Gaming | 65 | 171 |
Household Products | 127 | 26 |
Information Services | 69 | 283 |
Insurance (General) | 19 | 693 |
Insurance (Life) | 24 | 15 |
Insurance (Prop/Cas.) | 51 | 71 |
Investments & Asset Management | 192 | 120 |
Machinery | 120 | 27 |
Metals & Mining | 92 | 37 |
Office Equipment & Services | 22 | 16 |
Oil/Gas (Integrated) | 4 | 13 |
Oil/Gas (Production and Exploration) | 269 | 19 |
Oil/Gas Distribution | 24 | 606 |
Oilfield Svcs/Equip. | 136 | 28 |
Packaging & Container | 24 | 43 |
Paper/Forest Products | 15 | 20 |
Power | 52 | 28 |
Precious Metals | 83 | 98 |
Publishing & Newspapers | 31 | 28 |
R.E.I.T. | 234 | 91 |
Real Estate (Development) | 20 | 146 |
Real Estate (General/Diversified) | 12 | 31 |
Real Estate (Operations & Services) | 57 | 23 |
Recreation | 63 | 50 |
Reinsurance | 2 | 153 |
Restaurant/Dining | 77 | 66 |
Retail (Automotive) | 26 | 20 |
Retail (Building Supply) | 17 | 202 |
Retail (Distributors) | 80 | 28 |
Retail (General) | 18 | 22 |
Retail (Grocery and Food) | 13 | 38 |
Retail (Online) | 70 | 319 |
Retail (Special Lines) | 89 | 25 |
Rubber& Tires | 4 | 15 |
Semiconductor | 72 | 109 |
Semiconductor Equip | 39 | 26 |
Shipbuilding & Marine | 10 | 30 |
Shoe | 11 | 27 |
Software (Entertainment) | 86 | 60 |
Software (Internet) | 30 | 90 |
Software (System & Application) | 363 | 144 |
Steel | 32 | 11 |
Telecom (Wireless) | 18 | 27 |
Telecom. Equipment | 91 | 66 |
Telecom. Services | 67 | 115 |
Tobacco | 17 | 33 |
Transportation | 18 | 24 |
Transportation (Railroads) | 8 | 20 |
Trucking | 33 | 18 |
Utility (General) | 16 | 26 |
Utility (Water) | 17 | 46 |
Total Market | 7053 | 61 |
Total Market (without financials) | 5878 | 62 |
Updated: Jan 2020
About Calithera Biosciences
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginas... CALA Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.